Weitere Informationen zur Eisenmangel und Herzinsuffizienz: https://go.amboss.com/podcast/eisenmangel https://go.amboss.com/podcast/herzinsuffizienz

Mehr zum AMBOSS-Podcast: https://go.amboss.com/podcast

Mehr zum Studientelegramm - aktuelle internistische Studien, präzise zusammengefasst: https://go.amboss.com/podcast/archiv-01

Alle Studien dieser Podcastfolge zum Nachlesen:

“Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients” , Beverbog et al. DOI: 10.1161/CIRCHEARTFAILURE.117.004519

“Comparison of the Effects of Oral Iron Treatment Every Day and Every Other Day in Female Patients with Iron Deficiency Anemia”, Oflas et al.
DOI: 10.1111/imj.14766.

“Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside‐1000 (Monofer®) versus ferric carboxy‐maltose (Ferinject®). A single center, cohort study”, Mulder et al. DOI: 10.1111/bcp.13805_

“Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions”, Adkinson et al. DOI: 10.1002/ajh.25060

“HOMe aFers 1: Eine Vergleichsstudie zur Therapie der Eisenmangelanämie mit Eisen-Carboxymaltose (Ferinject) und Eisen-Isomaltose (Monofer)”, Emrich et al. DOI:10.1186/s12916-020-01643-5

“Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia Two Randomized Clinical Trials”, Wolf et al. DOI:10.1001/jama.2019.22450

Kommentar Dr. Wolf , DOI: 10.1111/apt.15437